A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma.

Trial Profile

A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Milatuzumab-doxorubicin conjugate (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Jan 2014 Status changed from suspended to completed according to ClinicalTrials.gov record .
    • 18 Jun 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 17 Nov 2012 Planned number of patients changed from 42 to 144.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top